Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N
Department of Molecular and Cellular Physiology, College of Medicine, University of Cincinnati, Ohio 45267-0576, USA.
J Pharmacol Exp Ther. 1997 Oct;283(1):375-83.
Levosimendan, a new Ca++-sensitizing and positive inotropic agent, was reported to act as a coronary vasodilator and protect ischemic myocardium. To elucidate the mechanisms of these actions, the possible electrophysiological effects of levosimendan on isolated rat ventricular cells were examined by the patch-clamp technique with whole-cell and single-channel recordings. Levosimendan (3 and 10 microM) markedly shortened action potential duration and activated an outward current at potentials positive to -70 mV. The increased current was abolished by glibenclamide, a blocker of the ATP-sensitive K+ (K[ATP]) current. Stimulation of K[ATP] current was dose dependent, with an EC50 value of 4.7 microM; a maximal effect occurred at 30 microM. The L-type Ca++ current was not affected by levosimendan (0.2-10 microM). In single-channel current recording in open cell-attached patches, K[ATP] channels, which had been inhibited by 0.3 mM ATP, were activated by levosimendan. However, levosimendan did not stimulate the K[ATP] channels that exhibited high spontaneous activity in ATP-free solution. Levosimendan also could not stimulate K[ATP] channels that had rundown in ATP-free solution. However, levosimendan could stimulate rundown K[ATP] channels that were reactivated by nucleotide diphosphates. K[ATP] channels inhibited by 0.5 mM AMP-PNP, a nonhydrolyzable ATP analog, were not stimulated by levosimendan; however, the channels were stimulated by levosimendan in the presence of 30 to 50 microM ADP. Levosimendan stimulates cardiac K[ATP] channels that are suppressed by intracellular ATP. It appears that levosimendan acts synergistically with nucleotide diphosphates. These properties of levosimendan may help protect ischemic myocardium because activation of K[ATP] channels by levosimendan would likely occur in ischemic regions in which intracellular ADP concentration is increased and intracellular ATP concentration is decreased.
左西孟旦是一种新型的钙增敏剂和正性肌力药物,据报道它具有冠状动脉扩张作用并能保护缺血心肌。为阐明这些作用机制,采用全细胞和单通道记录的膜片钳技术,研究了左西孟旦对离体大鼠心室细胞可能的电生理效应。左西孟旦(3和10微摩尔)显著缩短动作电位时程,并在电位高于 -70毫伏时激活外向电流。格列本脲(一种ATP敏感性钾电流(K[ATP])阻滞剂)可消除增加的电流。K[ATP]电流的刺激呈剂量依赖性,半数有效浓度(EC50)值为4.7微摩尔;在30微摩尔时出现最大效应。左西孟旦(0.2 - 10微摩尔)对L型钙电流无影响。在开放细胞贴附式膜片的单通道电流记录中,被0.3毫摩尔ATP抑制的K[ATP]通道被左西孟旦激活。然而,左西孟旦不能刺激在无ATP溶液中具有高自发活性的K[ATP]通道。左西孟旦也不能刺激在无ATP溶液中已衰减的K[ATP]通道。然而,左西孟旦可刺激被核苷酸二磷酸重新激活的衰减K[ATP]通道。被0.5毫摩尔AMP - PNP(一种不可水解的ATP类似物)抑制的K[ATP]通道未被左西孟旦刺激;然而,在30至50微摩尔ADP存在时,这些通道被左西孟旦刺激。左西孟旦刺激被细胞内ATP抑制的心脏K[ATP]通道。左西孟旦似乎与核苷酸二磷酸协同作用。左西孟旦的这些特性可能有助于保护缺血心肌,因为左西孟旦对K[ATP]通道的激活可能发生在细胞内ADP浓度升高而细胞内ATP浓度降低的缺血区域。